



Biocon Limited
20th KM, Hosur Road
Electronic City
Bangalore 560 100, India
T 91 80 2808 2808
F 91 80 2852 3423

CIN : L24234KA1978PLC003417

www.biocon.com

August 14, 2020

To The Manager BSE Limited Department of Corporate Services Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001 Scrip Code – 532523	To The Manager, National Stock Exchange of India Limited Corporate Communication Department Exchange Plaza, Bandra Kurla Complex Mumbai – 400 050 Scrip Symbol - Biocon
---	---

Subject: Disclosure pursuant to SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2020/84 dated May 20, 2020 ("SEBI Circular") – Impact of Covid-19 pandemic.

Dear Sir/Madam,

Please find enclosed the disclosure on impact of COVID-19 pandemic on our Company as required under SEBI Circular as Annexure A.

The above information will also be available on the website of the Company at www.biocon.com.

Kindly take the same on record and acknowledge.

Thanking You,

Yours faithfully,

For **Biocon Limited**

Mayank Verma



Mayank Verma
Company Secretary and Compliance Officer

Annexure A

S. No.	Particulars	Disclosures
1.	Impact of the COVID-19 on the business.	<p>The Covid-19 pandemic has affected business operations across various sectors of the global economy with restrictions on movement of people and goods including lockdowns in India and various other countries.</p> <p>We operate in the pharmaceutical sector, which the Indian government had categorised under essential services. This has enabled us to continue the manufacturing and selling of pharmaceutical products, with fewer challenges on people movement and supply chain.</p> <p>As per the current assessment of the situation based on internal and external information available to date, we believe that the impact of Covid-19 on our business has not been significant.</p>
2.	Ability to maintain operations including the factories/ units/ office spaces functioning and closed down.	<p>At present, the Company is able to maintain its operations at all manufacturing locations to ensure uninterrupted supply of pharma products.</p> <p>We have implemented several initiatives across our facilities including temperature check during entry, mandatory wearing of masks, social distancing at the work place, proper and timely sanitization of work places etc., for ensuring safety of our employees and business continuity.</p> <p>Employees in manufacturing, quality and R&D continue to report at the required strength to our various sites.</p> <p>As precautionary measure, we have asked a substantial number of employees, especially those under support functions, such as Finance, Marketing, HR, IT and administration to work remotely from home.</p> <p>A dedicated intranet site provides employees with important information related to Covid-19 guidelines and status updates.</p>
3.	Schedule, if any, for restarting the operations.	Refer to Point 2 above
4.	Steps taken to ensure smooth functioning of operations.	<p>The business operations are continuing as mentioned in Point 2 above.</p> <p>Critical levers to support enterprise resilience have been identified which include focus on overall people safety; transparent communication; continuation of critical operations</p>

		<p>such as procurement, production, sales and disposal of waste; compliance and governance; relooking at cash and liquidity management in the changing circumstances and prioritization/rationalization of spends.</p> <p>Furthermore, remote working and cyber security, safe plant operations, impact assessment on R&D and capex spends and availability of insurance coverage and contract liabilities have been evaluated and key mitigation actions put in place to support the implementation of business continuity plans and continued safe operations.</p>
5.	Estimation of the future impact of COVID-19 on our operations.	<p>The business operations are continuing as mentioned in Point 2 above</p> <p>However, there remain uncertainties associated with the nature and duration on how this pandemic will evolve. The impact assessment of Covid-19 is a continuing process and the Company is monitoring closely the impact of the same on employee safety, business operations, financial performance, customers, vendors and business partners.</p>
6.	Impact of COVID-19 on:	
	• Capital and financial resources	None
	• Profitability	Not Material
	• Liquidity position	None
	• Ability to service debt and financing arrangements	None
	• Assets	None
	• Internal financial reporting and control,	All internal controls and financial reporting systems continue to be fully operational.
	• Supply chain and	Not Material
	• Demand for its products/ services	Not Material
7.	Existing contracts/ agreements where non-fulfilment of the obligations by any party will have significant impact on the listed entity's business.	No significant impact of such non- fulfilment of the obligations by any party on our business is expected.
8.	Other relevant material updates about the listed entity's business.	None. The Company will provide an update as and when there is any material impact on business.